ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
54 announcements with these filters
Shilpa Biologicals settled a claim with Sartorius Stedim India for ₹9 Crore. The agreement was signed before the Commercial Court, Bengaluru.
Shilpa Biologicals commissioned a state-of-the-art ADC GMP manufacturing facility, expanding its high‑potency biopharma capabilities. The facility is now operational, positioning the group as a CDMO partner.
Shilpa Biologicals commissioned a cutting‑edge ADC GMP manufacturing facility. The plant expands Shilpa Medicare’s CDMO capabilities for oncology drug substances.
Shilpa Medicare's subsidiary will invest €7 million (₹77 Crore) for a 30.4% stake in Gate2Brain. The partnership advances brain cancer therapies through strategic manufacturing and regulatory collaboration.
Shilpa Medicare's Bengaluru facility concluded a USFDA inspection with five procedural observations. The company expects no material impact on operations and will respond within timelines.
Shilpa Medicare Limited filed its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory compliance with no material deviations or penalties.
Shilpa Medicare reported its highest-ever quarterly revenue of ₹439cr (+30% YoY) and full-year FY26 revenue of ₹1,549cr (+18% YoY), driven by API and formulation vertical integration.
Shilpa Medicare reported its highest-ever quarterly revenue and EBITDA, signaling a shift from a long investment cycle to asset sweating and operational leverage.
Shilpa Medicare has initiated a postal ballot for shifting its registered office between states. Shareholders will vote on altering the Memorandum of Association via special resolution.
Shilpa Medicare delivered record FY26 performance with 18% revenue growth and 30% EBITDA growth. Strategy focuses on high-value CDMO partnerships, specialized formulations like NorUDCA, and a robust biosimilar pipeline.
Shilpa Medicare is seeking shareholder approval to shift its registered office from Karnataka to Mumbai, Maharashtra. The move aims to improve access to financial institutions and investors.
Shilpa Medicare appointed Aneja Associates as Internal Auditor for a twelve-month term. The firm brings forty years of governance and risk experience to the company.
Shilpa Medicare recommended a final dividend of ₹0.6 per equity share for 2026. This distribution reward remains subject to upcoming shareholder approval.
Shilpa Medicare Ltd reported revenue from operations of ₹437 Cr (+32.1% YoY) and net profit of ₹107.8 Cr (+643.4% YoY) for Q4 FY26.
Shilpa Medicare reported audited FY26 results and recommended a Re. 0.60 final dividend. The board also approved a 28% strategic investment in Neo Green Power.
Shilpa Medicare reported record quarterly revenue and EBITDA, signaling a shift from heavy R&D investment to commercial execution across API, formulations, and biologics.
Shilpa Medicare scheduled a board meeting for 22 May 2026 to approve FY26 financial results. Directors will also consider a dividend recommendation for the financial year.
Shilpa Medicare Limited has appointed Dr. Vellaian Karuppiah as Chief Operating Officer (COO) effective April 23, 2026. Dr. Karuppiah brings over 33 years of pharmaceutical experience from firms like Gland Pharma and Dr. Reddy’s. He is expected to strengthen formulation business operations and enhance operational efficiencies.
Shilpa Medicare Limited has appointed Dr. Vellaian Karuppiah as Chief Operating Officer (COO) – Formulations, effective 23 April 2026. Dr. Karuppiah brings over 33 years of pharmaceutical experience from firms like Gland Pharma and Dr. Reddy’s. He is expected to strengthen the company’s formulation business and operational efficiencies.
Mr. Jayant Karajgi, the Chief Operating Officer (COO) - Formulations of Shilpa Medicare Limited, retired from his position effective April 22, 2026. He was categorized as Senior Management Personnel.
Dr. Jayant Karajgi, Chief Operating Officer (COO) – Formulations of Shilpa Medicare Limited, retired from the company effective April 22, 2026. He also ceased to be a Senior Management Personnel (SMP) on the same date. This leadership transition follows regulatory disclosure requirements under SEBI (LODR) Regulations, 2015.
Shilpa Medicare Limited informed stock exchanges that it does not qualify as a Large Corporate for the financial year ended March 31, 2025. The company reported zero outstanding long-term borrowings under the SEBI debt framework. India Ratings and Research assigned the company an A+ credit rating with a positive outlook.
Shilpa Medicare Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. Issued by KFin Technologies Limited, the certificate confirms that security details for dematerialized and rematerialized shares have been furnished to the relevant stock exchanges.
Shilpa Medicare Limited's promoter group, led by Mr. Omprakash Innani, disclosed a 40.13% aggregate holding as of March 31, 2026. The filing confirms various share pledges made by promoter group members, including Mr. Vishnukant Bhutada and Mr. Ramakant Innani, during the financial year. Total promoter group holding stands at 7,84,96,648 shares.